This article is more than 5 years old. Information may no longer be current.

Allergan responds to Valeant, Pershing Square counterclaims

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Allergan has filed an answer in the U.S. District Court for the Central District of California in response to Valeant Pharmaceuticals and Pershing Square Capital Management counterclaims, according to an Allergan press release.

The response addresses counterclaims from Valeant and Pershing Square regarding Allergan’s previous statements on the unsustainability of Valeant’s underlying business model, according to the release.

The federal court case is Allergan, Inc. vs. Valeant Pharmaceuticals International, Inc., No. 14-CV-1214-DOC (ANx) (C.D. Cal.).